Imagene AI
AI-based molecular testing for cancer.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor | €0.0 | round | |
* | $23.0m | Series B | |
| Total Funding | 000k | ||
Related Content
Imagene AI operates within the digital pathology and precision medicine sectors, offering an AI-powered platform that delivers real-time molecular intelligence from digitized biopsy images. The company's core technology is a foundation model trained on over 1.5 million pathology slides, which facilitates the rapid profiling of a wide range of biomarkers for cancer.
This capability aims to significantly reduce the time required for patient diagnosis and treatment matching, which traditionally takes several weeks. By providing immediate molecular insights, the platform supports healthcare providers in making timely and informed decisions for precision oncology. The business model is structured as a Software as a Service (SaaS), providing adaptive capabilities for biomarker discovery and patient identification to its clients, which primarily include pharmaceutical companies and healthcare providers.
Recent funding rounds, including a significant Series B investment, underscore investor confidence in the company's approach to transforming cancer diagnostics and treatment. The platform's ability to function as a tool for precision medicine places it at the intersection of AI development and clinical application in oncology.
Keywords: digital pathology, precision medicine, AI diagnostics, biomarker discovery, oncology, molecular intelligence, SaaS, biopsy analysis, cancer treatment, healthcare technology